Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
NCT02045836
Completed
The purpose of this study is to assess the immunogenicity, reactogenicity and safety of the GSK Biologicals HZ/su candidate vaccine when its first dose is co-administered with Pneumovax 23™ vaccine in adults aged 50 years or older.The impact of HZ/su vaccine on Pneumovax 23™ vaccine immune response will also be evaluated.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Golden, Colorado +8 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
NCT01798056
Completed
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/19/2021
Locations: GSK Investigational Site, Halifax, Nova Scotia +27 locations
Conditions: Herpes Zoster, Herpes Zoster Vaccine
Register for Updates
Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants
NCT00213265
Completed
We plan to study whether the 7-valent pneumococcal conjugate vaccine (Prevnar™) is safe and effective in protecting children who have had a solid organ transplantation and healthy children from pneumococcal infections. We expect that two or more doses of Prevnar™ will result in similar antibody responses among transplant recipients compared with healthy control subjects, and that children who have undergone solid organ transplant will have a similar number of serious vaccine-related adverse eve... Read More
Gender:
ALL
Ages:
Between 2 months and 18 years
Trial Updated:
02/10/2021
Locations: The Hospital for Sick Children, Toronto, Ontario
Conditions: Organ Transplant, Immunosuppression
Register for Updates
A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age
NCT03652610
Completed
MenACWY (Menveo) is a GSK vaccine intended for protection against disease caused by meningococcal bacteria groups A, C, W and Y in infants, children and adults, licensed in more than 60 countries. The purpose of this study is to compare the immunogenicity of the currently licensed MenACWY vaccine with the investigational MenACWY liquid vaccine.
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
01/20/2021
Locations: GSK Investigational Site, Blacktown, New South Wales +29 locations
Conditions: Infections, Meningococcal
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +301 locations
Conditions: Staphylococcal Vaccine
Register for Updates
High Dose vs. Standard Influenza Vaccine in Adult SOT
NCT03139565
Completed
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine. This will be a single center prospective observer-blind randomized controlled trial conducted at the Toronto General Hospital Multi-Organ Transplant Unit, University Health Network, Toronto, Ontario, Canada.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2020
Locations: University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto, Ontario
Conditions: Influenza, Immunosuppression
Register for Updates
Early Flu Shots in SOT
NCT03327987
Withdrawn
Although time from transplant has been a factor in vaccine response, there is limited data on immunizations that occur in the first post-transplant year, and there are no data that suggest influenza vaccination early post-transplant may have any adverse effects on the graft. It is suggested that early vaccinations may lead to reduced immunogenicity due to induction immunosuppression. However, not vaccinating patients may leave them vulnerable to influenza infection for a period of time. This stu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2020
Locations: University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto, Ontario
Conditions: Influenza, Solid Organ Transplant
Register for Updates
Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.
NCT01991561
Completed
A phase 2, Randomized, Observer-blind, Multicenter, Dose-Ranging Study to Evaluate the Immunogenicity, Safety, and Tolerability of the plant-made H5 VLP Influenza vaccine adjuvanted with Alhydrogel or Glucopyranosyl-lipid adjuvant in squalene emulsion (GLA-SE), in healthy adults 18-60 years of age.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/08/2020
Locations: INC Research, Toronto, Ontario +1 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
NCT02768805
Completed
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/08/2020
Locations: Broward Research Group (BRG), Hollywood, Florida +8 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Immunogenicity of Gardasil and Twinrix and the Effect of a Dose of Gardasil or Cervarix Given 42 Months Later.
NCT01456715
Completed
Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: * The immunogenicity and safety of Gardasil and Twinrix when co-administered. * The immunogenicity and safety of Cervarix when administered to subjects previously vaccinated with Gardasil. The main objective of the first phase of this clinical trial was: • To assess and compare the immunogenicity of Gardasil and Twinrix Junior when co-administered or administered at one month interval accordin... Read More
Gender:
FEMALE
Ages:
Between 12 years and 14 years
Trial Updated:
03/04/2020
Locations: Laval University Research Hospital Center, Quebec, Not set
Conditions: Human Papillomavirus
Register for Updates
Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population
NCT02236052
Completed
This is a multiple sites phase II trial, randomized, observer-blind, dose ranging, placebo-controlled study to evaluate the immunogenicity, safety, and tolerability of a single intramuscular injection of plant-based Seasonal VLP Quadrivalent Influenza Vaccine administered in elderly subjects (50 years old and more). A total of four hundred fifty (450) subjects will be randomized in six (6) groups of 75 subjects to receive one injection of either a non-adjuvanted low, medium or high dose level o... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/31/2019
Locations: MUHC-Vaccine Study Centre, Pierrefonds, Quebec +2 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults
NCT02831751
Completed
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to evaluate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria and to evaluate if the immunogenicity and the safety profile of the Quadrivalent VLP Vaccine is acceptable and comparable to that of the FluLa... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
10/23/2019
Locations: Paradigm Research - Redding, Redding, California +14 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates